MiNA Therapeutics Limited
MiNA Therapeutics is a clinical-stage UK biopharmaceutical company developing small activating RNA (RNAa) therapeutics.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
MiNA Therapeutics is a London-based biopharmaceutical company that describes itself as the global leader in small activating RNA therapeutics, or RNAa. Its RNAa medicines are designed to restore or boost normal function of genes and thereby protein-modulated pathways in cells. The company is advancing a proprietary pipeline with an initial focus on genetic medicine while collaborating with pharmaceutical partners across other therapeutic areas. Its first RNAa medicine has been evaluated in clinical trials in over 130 patients, and the company states its team has developed a systematic approach to take new RNAa medicines from idea to clinical trial in about two years.
History
MiNA Therapeutics is a biopharmaceutical company based in London, United Kingdom. Robert Habib joined MiNA as founding Chief Executive Officer in 2013 and has overseen MiNA's growth into a clinical stage company with a pipeline of new medicines and collaborations with leading pharmaceutical partners; during his tenure MiNA has established itself as the leader in RNA activation therapeutics, attracting over $100m of funding. Bríd Ryan joined MiNA in 2021 and was promoted to Chief Scientific Officer in 2025. Robin Wright was appointed Chief Financial Officer in 2021. The company has entered into research collaborations, including a multi-year collaborative research agreement with Imperial College London in 2015, a strategic investment of £35m by Sosei Group Corporation in May 2017, a multi-target research collaboration with BioMarin in 2023, and a research collaboration with Nippon Shinyaku in 2024 to develop RNAa therapeutics targeting rare neurodegenerative diseases.
Products and positioning
Global leader in small activating RNA therapeutics (RNAa)
RNAa therapeutics
A new class of medicines that can restore or boost normal function of genes and thereby protein-modulated pathways in cells.
MTL-CEBPA
MiNA's first RNAa medicine, evaluated in clinical trials in over 130 patients.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/mina-therapeutics-limited-united-kingdom · Editorial policy · How profiles are compiled